Group 1 - The core viewpoint emphasizes the need for deepening reforms to stimulate the vitality of multi-level markets, particularly through the implementation of measures for the Sci-Tech Innovation Board and a comprehensive package of reforms for the Growth Enterprise Market [1] - The underwriting scale of Sci-Tech bonds has significantly increased, with 68 securities firms acting as lead underwriters, collectively underwriting 381.39 billion yuan in the first half of the year, representing a year-on-year increase of over 50%, indicating strong support from the capital market for technological innovation [1] - The new regulations for the Sci-Tech Innovation Board and the Growth Enterprise Market are being steadily implemented, enhancing the inclusiveness of the capital market and better supporting the financing needs of early-stage growth companies [1] Group 2 - The Sci-Tech Innovation Board 100 ETF (588120) tracks the Sci-Tech 100 Index (000698), which can fluctuate by up to 20% in a single day, selecting 100 securities with larger market capitalization and better liquidity from the Sci-Tech Innovation Board, covering various high-tech fields such as information technology, biomedicine, and new materials [1] - Investors without stock accounts can consider the Guotai CSI Sci-Tech Innovation Board 100 ETF Initiated Link A (019866) and Guotai CSI Sci-Tech Innovation Board 100 ETF Initiated Link C (019867) [1]

Group 1 - The pharmaceutical and biotech sectors are experiencing high growth, with a recommendation for Pharma and Biopharma/Biotech companies that are expected to see a revaluation of their value and performance entering a growth phase [1] - The medical device industry is likely to benefit from policy optimization, as recent statements from relevant authorities indicate support for innovation and a move away from simple lowest-bid procurement practices [1] - The A-share pharmaceutical sector outperformed, with the medical device sub-sector rising by 4.4%, indicating a sustained improvement in industry sentiment [1] Group 2 - The Guotai Medical ETF (159377) tracks the innovative pharmaceutical index (399275), which focuses on companies involved in biotechnology, pharmaceuticals, and related medical services, emphasizing those with high R&D investment and growth potential [1]

Group 1 - The Shanghai municipal government has approved a plan to accelerate the integration of AI and manufacturing, indicating strong support for the fusion of these sectors [1] - The China Securities Regulatory Commission (CSRC) emphasized the need to invigorate multi-level market vitality and implement reforms in the Sci-Tech Innovation Board, which will enhance the capital market's inclusiveness and better support financing needs for early-stage growth companies [1] - In the first half of the year, the underwriting scale of Sci-Tech bonds reached 381.39 billion yuan, a year-on-year increase of 56.48%, reflecting strong financing demand in the Sci-Tech sector [1] Group 2 - The active trading environment and policies guiding long-term capital inflow are expected to consolidate market confidence and continuously optimize the financing environment for Sci-Tech enterprises [1] - The Guotai Sci-Tech Innovation Index ETF (589630) tracks the Sci-Tech Innovation Index (000680), which can fluctuate by up to 20% in a single day, reflecting the overall performance of the Sci-Tech board market [1] - The index includes listed companies in high-tech fields such as information technology, biomedicine, and new energy, showcasing the development status of innovative enterprises with significant growth characteristics [1]

（文章来源：每日经济新闻） 科创综指ETF国泰（589630）跟踪的是科创综指（000680），当日涨跌幅可达20%。该指数涵盖了在科 创板上市的所有股票，旨在反映科创板整体市场表现。科创综指成分股多为科技创新型企业，覆盖信息 技术、生物科技等多个前沿领域，强调科技与创新属性，行业配置上侧重于新兴技术和高成长性行业。 民生证券指出，证监会年中工作会议强调激发多层次市场活力，推动科创板改革举措落地，推出深化创 业板改革的一揽子举措。科创债承销规模显著增长，上半年68家券商承销金额达3813.91亿元，同比增 长56.48%，显示资本市场对科技创新领域的支持力度持续加大。科创板与创业板新规稳步落地实施， 有助于提升资本市场包容性，更好支持成长初期企业融资需求。 ...

Group 1 - The core viewpoint emphasizes the importance of high dividend strategies amidst rising uncertainty, suggesting a focus on stable dividend stocks over cyclical ones due to their defensive attributes and ability to provide predictable returns [1] - The report highlights that the global demand and the turning point for domestic "real estate + infrastructure" have not yet arrived, indicating a cautious outlook for these sectors [1] - It recommends stable dividend stocks, such as those in banking and public utilities, as a primary investment strategy during the current market phase, especially in a low interest rate environment [1] Group 2 - The Hong Kong Dividend ETF (510720) tracks the Shangguo Dividend Index (000151), which selects listed companies with strong dividend records, covering traditional industries that focus on stable returns and value investment [1] - For investors without stock accounts, it suggests considering the Guotai Shanghai Stock Exchange State-Owned Enterprise Dividend ETF Initiated Link A (021701) and Link C (021702) as alternative investment options [1]

Group 1 - The Ministry of Industry and Information Technology and the National Energy Administration proposed to promote the orderly exit of backward photovoltaic production capacity, strengthen technological innovation, and guide the high-quality development of the industry [1] - In June, the domestic newly installed photovoltaic capacity was 14.36 GW, down 38% year-on-year and 85% month-on-month, mainly due to the end of the "531" policy rush and some projects being delayed due to unclear returns [1] - The annual installation is still expected to grow, with forecasts of 270-300 GW and 570-630 GW for domestic and global installations respectively by 2025 [1] Group 2 - The energy consumption standard for polysilicon is expected to be significantly raised, with the revised first-level standard set at ≤5 kgce/kg, currently only met by granular silicon enterprises [1] - The photovoltaic glass segment has begun to reduce production due to oversupply, with inventory decreasing by 9.1% week-on-week, and rising raw material prices driving demand for component stockpiling [1] - Recent signals against excessive competition have been released, and under the current industry loss conditions, photovoltaic glass prices may rise to near cost price, promoting profit recovery [1] Group 3 - The Photovoltaic 50 ETF (159864) tracks the photovoltaic industry index (931151), which selects listed companies involved in silicon materials, battery components, and photovoltaic power generation systems to reflect the overall performance of the photovoltaic industry chain [2] - The photovoltaic industry index exhibits high growth and volatility characteristics, serving as an important tool for investors to allocate resources in the renewable energy and sustainable development sectors [2] - Investors without stock accounts can consider the Guotai CSI Photovoltaic Industry ETF Initiated Link A (013601) and Link C (013602) [2]

Core Viewpoint - The Central Political Bureau of the Communist Party of China emphasizes "technological innovation leading the development of new productive forces," indicating a shift towards technology-driven economic policies and a focus on high-quality development [1] Group 1: Economic Policy and Market Trends - The meeting highlights the transition of economic work towards technology innovation-driven strategies, suggesting that policies may increasingly favor sectors represented by "new productive forces," particularly in technology [1] - There is a potential shift in market style from being driven by cyclical factors to being driven by technological innovation, which may benefit sectors such as AI and robotics [1] - The emphasis on "governing enterprises' disorderly competition according to law" and "promoting capacity governance in key industries" reflects a commitment to regulating the development of the technology industry [1] Group 2: Investment Opportunities - The Science and Innovation Entrepreneurship ETF (588360) tracks the Science and Innovation 50 Index (931643), which can fluctuate by up to 20% in a single day, reflecting the overall performance of major securities in the technology innovation sector [1] - The index includes 50 securities selected from the Science and Technology Board and the Growth Enterprise Market, focusing on those with larger market capitalization and better liquidity, covering industries such as information technology and healthcare [1] - Investors without stock accounts can consider the Guotai CSI Science and Innovation Entrepreneurship 50 ETF Initiated Link C (013307) and Link A (013306) for exposure to this sector [1]

Group 1 - The core viewpoint of the article emphasizes the China Securities Regulatory Commission's (CSRC) mid-year work meeting, which highlights the need to stimulate the vitality of a multi-tiered market and the introduction of a comprehensive package of measures to deepen the reform of the ChiNext board [1] - The formal implementation of the third set of standards on the ChiNext board aims to support high-quality, unprofitable innovative enterprises in going public, enhancing the inclusiveness of the capital market to better meet the financing needs of early-stage growth companies [1] - The steady implementation of new regulations for the Sci-Tech Innovation Board and ChiNext is expected to benefit leading securities firms with rich project reserves, particularly those deeply engaged in the Sci-Tech sector, as the recovery of investment banking revenues is anticipated [1] Group 2 - The active trading environment in the capital market is expected to continue, leading to a sustained trend of performance recovery for securities firms [1] - The Guotai ETF (159375), which tracks the ChiNext 50 Index (399673), can experience daily fluctuations of up to 20%, reflecting the performance of 50 large-cap, liquid companies in the ChiNext market, covering sectors such as information technology and healthcare [1] - The ChiNext 50 Index is designed to represent the overall performance of listed companies on the ChiNext market, characterized by growth style and technological innovation [1]

注：如提及个股仅供参考，不代表投资建议。指数/基金短期涨跌幅及历史表现仅供分析参考，不预示 未来表现。市场观点随市场环境变化而变动，不构成任何投资建议或承诺。文中提及指数仅供参考，不 构成任何投资建议，也不构成对基金业绩的预测和保证。如需购买相关基金产品，请选择与风险等级相 匹配的产品。基金有风险，投资需谨慎。 （文章来源：每日经济新闻） 民生证券指出，证监会2025年年中工作会议强调激发多层次市场活力，推动科创板改革举措落地，推出 深化创业板改革的一揽子举措。6月证监会主席表示将在创业板启用第三套标准，支持优质未盈利创新 企业上市。科创板与创业板新规稳步落地实施，有助于提升资本市场包容性，更好支持成长初期企业融 资需求。 科创板100ETF（588120）跟踪的是科创100指数（000698），当日涨跌幅可达20%。该指数从科创板中 选取市值中等、流动性较好的100只证券作为指数样本，以反映科创板中盘股的整体表现。指数成分股 覆盖多个行业，重点聚焦科技创新领域，包括信息技术、生物医药等，充分体现了科创板企业的创新活 力和成长潜力。 没有股票账户的投资者可关注国泰上证科创板100ETF发起联接C（019867 ...

科创创新药ETF国泰（589720）聚焦科创板创新药企业，跟踪汇聚30家代表性优质公司的上证科创 板创新药指数，以高成长biotech为主，这些企业管线潜力大、研发投入强，指数创新属性突出，有助于 更精准捕捉行业核心成长动能。指数表现弹性较强，产品20%涨跌幅限制使其更贴合板块波动，是成长 型投资者分享创新药红利的便捷选择。 消息面上，为鼓励药品研发创新，国家医保局制定了"新上市药品首发价格机制"。 相关机构表示，我国创新药产业近年来在全球舞台上绽放出蓬勃的发展活力，2025 年更是在多个 维度实现了突破性进展。从出海进程的加速推进，到在 ASCO 大会等国际学术舞台上的亮眼表现，再 到国内政策红利的持续释放，创新药行业正步入黄金发展阶段。当下市场活跃资金对创新药行业的关注 度也日益攀升，为行业的进一步发展注入了强劲动力。 展望后市，创新药行业在出海持续突破、政策红利不断释放以及中国创新药企业研发实力稳步提升 的多重驱动下，正迎来广阔的发展空间，具备较好的投资机会。想要把握创新药行业高成长潜力与国际 化浪潮机遇的小伙伴们，可以关注科创创新药 ETF 国泰（589720）。 注：如提及个股仅供参考，不代表投资建 ...